secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adverum Biotechnologies, Inc. (—)
CIK:        0001501756
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001628280-24-022224
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adverum Q1 net loss $24.8M; cash $193.3M; LUNA Phase 2 interim data to be presented in July
--------------------------------------------------------------------------------

- Net loss of $24.8M ($1.50 per share) vs $29.1M in Q1 2023; R&D and G&A expenses decreased.
- Cash, equivalents and short-term investments $193.3M as of March 31, 2024, up from $96.5M year-end; funds into late 2025.
- LUNA Phase 2 interim analysis (26-week landmark) to be presented at ASRS July 17–20, 2024.
- Preliminary LUNA data: 94% and 90% reduction in annualized anti-VEGF injections at 2E11 and 6E10 doses; 85% and 68% injection-free at 26 weeks.
- Ixo-vec generally well tolerated; no serious adverse events, vasculitis, or vascular occlusion reported.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501756/000162828024022224/0001628280-24-022224-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501756/000162828024022224/advm-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-022224

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer